News from resverlogix corp A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( OTC-BB:XPWR)

Apr 28, 2015, 07:42 ET

Resverlogix y Shenzhen Hepalink Pharmaceutical Co., Ltd. anuncian un acuerdo de combinación de licencia y valores

- Resverlogix y Shenzhen Hepalink Pharmaceutical Co., Ltd., con sede en China, anuncian un acuerdo de combinación de licencia y...

Apr 27, 2015, 07:00 ET

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in...

Apr 07, 2015, 07:30 ET

Resverlogix Receives Two Patents for RVX-208 in China

CALGARY, April 7, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announces that it has received two China...

Apr 07, 2015, 07:30 ET

Resverlogix recibe dos patentes para RVX-208 en China

Resverlogix Corp. ("Resverlogix" o "la compañía") (TSX: RVX) anunció que ha recibido dos aprobaciones de patente en China que...

Mar 16, 2015, 13:30 ET

Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)

RVX-208 the first selective bromodomain extra-terminal (BET) protein inhibitor being developed for patients with high residual risks of...

Mar 04, 2015, 09:00 ET

Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

Emerald Logic FACET software generates predictive models and identifies novel variables driving RVX-208 drug efficacy, safety and reduced MACE...

Jan 14, 2015, 20:00 ET

Resverlogix Presents at Biotech Showcase During JP Morgan Week

SAN FRANCISCO, CA, Jan. 14, 2015 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) (the "Company") today announced that Donald McCaffrey, president and...

Nov 03, 2014, 17:05 ET

Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development

CALGARY, Nov. 3, 2014  /PRNewswire/ -  Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as...

Oct 08, 2014, 18:01 ET

Resverlogix Announces Annual General Meeting Voting Results

TSX Exchange Symbol:  RVX CALGARY, Oct. 8, 2014 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual...

Oct 01, 2014, 14:00 ET

Resverlogix Corporate Update Conference Call & Webcast Announcement

TSX Exchange Symbol: RVX CALGARY, Oct. 1, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) will be hosting a corporate update conference call and...

Sep 02, 2014, 16:06 ET
Sep 02, 2014, 14:51 ET

RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 %

Vorgestellt in der "State of the Art and Featured Research Session" beim Kongress des europäischen Kardiologenverbandes...

Sep 02, 2014, 08:30 ET

RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus

Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol:...

Aug 15, 2014, 17:00 ET

Resverlogix Corp. Closes Additional $30 million from Citibank Loan

TSX Exchange Symbol: RVX CALGARY, Aug. 15, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has closed...

Aug 13, 2014, 17:01 ET

Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan

TSX Exchange Symbol: RVX CALGARY, Aug. 13, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that holders...

Jul 24, 2014, 07:36 ET

RVX-208 reduce los principales efectos secundarios cardiovasculares de la diabetes mellitus

  - RVX-208 reduce significativamente los principales efectos secundarios cardiovasculares (MACE) en pacientes con diabetes...

Jul 23, 2014, 09:00 ET

RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus

In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose...

Jul 03, 2014, 19:21 ET

Resverlogix Secures an Additional $30 million from Citibank Loan

Special Meeting of Shareholders Called to Approve TSX Exchange Symbol: RVX CALGARY, July 3, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX)...

May 21, 2014, 08:00 ET

Leading Life Science Publication SciBX Highlights RVX-208

"Most Advanced Epigenetic Drug in Clinical Development" TSX Exchange Symbol: RVX CALGARY, May 21, 2014 /CNW/ - Resverlogix Corp. ("Resverlogix"...

Mar 31, 2014, 13:00 ET

Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014

"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation" TSX Exchange Symbol: RVX CALGARY, March 31,...